Concerns About the Approval of Nusinersen Sodium by the US Food and Drug Administration

JAMA Intern Med. 2018 Jun 1;178(6):743-744. doi: 10.1001/jamainternmed.2018.0869.

Authors

Martha S Gerrity¹, Vinay Prasad^{2

3}, Adam J Obley¹

Affiliations

¹ Division of General Internal Medicine and Geriatrics, Oregon Health & Sciences University, Portland.
² Division of Hematology Oncology, Knight Cancer Institute, Portland, Oregon.
³ Center for Health Care Ethics, Oregon Health & Sciences University, Portland.

PMID: 29710299
DOI: 10.1001/jamainternmed.2018.0869

No abstract available

MeSH terms

Drug Approval
Humans
Infant
Oligonucleotides / economics
Oligonucleotides / therapeutic use*
Randomized Controlled Trials as Topic
Spinal Muscular Atrophies of Childhood / drug therapy*
United States
United States Food and Drug Administration

Substances

Oligonucleotides
nusinersen